ROXALL Medizin GmbH

DUBLIN, March 3, 2023 /PRNewswire/ -- The "Allergy Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Allergy Diagnostics Market to Reach $8.3 Billion by 2030 The global market for Allergy Diagnostics estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$8.3 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2022-2030. Assay Kits, one of the segments analyzed in the report, is projected to record a 11% CAGR and reach US$4.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 10.1% CAGR for the next 8-year period. The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 15% CAGR The Allergy Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 15% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 9.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2030. What`s New for 2023? Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession. Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and Research Platform Complimentary updates for one year Key Topics Covered: MARKET TRENDS & DRIVERS Development of Effective Allergy Diagnostic Products Cuts Down on Healthcare Spending Labs Embrace Automation and Advanced Allergy Tests for Fast Turnaround Times Food Allergies - A Major and Growing Concern Select Digital Technologies to Provide Help in Managing Food Allergy Food Allergies Create Opportunities for Food Allergy Testing ELISA Gains Lead as Preferred Food Testing Method Need to Offer Quality Services at Affordable Costs Prompts Labs to Consider Reagent Rental Agreements In-Vitro IgE Molecular Diagnostics to Transform Allergy Testing Market Macro Array Diagnostics Unveils Allergy Explorer for Allergy Diagnostics Rising Alcohol and Drug Abuse Increases Demand for Allergy Diagnostics Increasing Cases of Allergies Drive Development of Advanced Allergy Diagnostics Solutions Focus on Single and Protein Allergens IgE Antibody Tests Allergy Diagnostic Reagents on Microchip Allergy Diagnosis Moves from Lab-based to Decentralized POC Tests Patch Test to Experience Healthy Growth SmartPractice Secures FDA Approval for T.R.U.E. Test(R) Patch Test for Pediatric Use Providers of Allergy Diagnostic Services Focus on Vertical Integration Allergic Diagnostic Challenges in Patients Enhanced Access to Allergy Diagnosis Medical Insurance & Instrument Allowances in the US Widen Market Prospects Typical Cost Structure for Allergy Testing Technological Advancements - Mobile Health Tools for Allergy Patients Technological Advancements - Nanotechnology for Allergy Diagnostics Application of Nanostructures for In-Vitro Diagnosis of Allergy Application of Nanostructures in Drug-sIgE Detection Application of Nanostructures for Detection of Allergen-sIgE Select Recent Launches in the Allergy Diagnostics Market to Bolster Market Expansion EUROIMMUM Develops EUROLINE DPA-Dx Pollen Southern Europe 1 Test for Pollen Allergies Hycor Biomedical Secures FDA Clearance for NOVEOS Allergy Testing System ASI Introduces IVT Allergy(R) 3 Screen Panel for Allergy Skin Testing CLA-1(TM) Luminometer In-Vitro Allergy Testing Platform for Accurate, Reliable Results Growth Drivers Increasing Prevalence and Incidence of Allergic Disorders to Drive the Demand for Allergy Diagnostics Atopic Dermatitis (Eczema) Prevalence Rates among Global Adult Population Environmental Changes and Pollution Aggravate Incidence of Allergic Reactions, Resulting in Increased Need for Allergy Diagnostics Major Environmental Factors with Link to Allergic Diseases Growing Number of Food Allergy Cases Fuels Demand for Allergy Testing Kits Prevalence Rate of Five Common Food Allergies among US Adults Factors Responsible for Rising Prevalence of Food Allergy Burgeoning Aging Population and Longer Life Expectancy to Drive Allergy Diagnostics Market Inadequate Knowledge about Food Allergy Inhibits Growth of Allergy Diagnostic Market Expensive Nature of Allergy Diagnostics Approaches Limits Market Growth New Regulations and Statutory Provisions to Affect Diagnostic Allergen Extracts MARKET OVERVIEW Allergens: A Prelude Key Allergy Stats Allergy: Symptoms and Causes Allergic Diagnostics: An Introduction Food Allergen Testing Impact of Covid-19 and a Looming Global Recession The Never-Ending "Race" Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond? Time is of Essence! What We Know So Far - "Vaccine Efficiency Against New Strains" With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them? With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness A Strong Yet Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 Allergy Diagnostics Market Under the Covid Lens Telemedicine Gains Prominence amid the Pandemic Global Allergy Diagnostics Market Set to Witness Rapid Growth With Allergies on the Rise for Whatever Reason Be It Our Neanderthal Genes or Hygiene Hypothesis or Vitamin D Hypothesis, the Need for Effective Diagnostics Has Never Been Greater Global Prevalence of Allergies (In Million) Assay Kits Dominate the Allergy Diagnostics Market Inhaled Allergens Segment to Witness Fastest Growth US Dominates the Allergy Diagnostics Market, While China to Witness the Fastest Growth Rising Demand for In-Vitro Diagnostic Tests for Allergy Diagnosis Recent Market Activity Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E) FOCUS ON SELECT PLAYERS (Total 100 Featured) Alk-Abello A/S Allergy Therapeutics PLC ALPCO Angsana Molecular & Diagnostics Laboratory Pte. Ltd. Astra Biotech GmbH biomerieux SA Demeditec Diagnostics GmbH EUROIMMUN Medizinische Labordiagnostika AG GA Generic Assays GmbH INDOOR Biotechnologies, Inc. Lincoln Diagnostics, Inc. Omega Diagnostics Group Plc R-Biopharm Ag Roxall Medizin GmbH Siemens Healthineers Stallergenes Greer Tecan Trading AG Theradiag Thermo Fisher Scientific Inc. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research-and-Markets Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

The single access procedure enables the treating physician not only to place Impella heart pumps in the ventricle via the 14 French Impella CP introducer sheaths, but also to insert other catheters and introducer sheaths Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment of heart disease in Europe. (Credit: Business Wire) Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment of heart disease in Europe. At Abiomed’s European headquarters in Aachen, Germany, Impella heart pumps have been developed and produced for more than 20 years to stabilize and recover the human heart. The single access procedure enables the treating physician not only to place Impella heart pumps in the ventricle via the 14 French Impella CP introducer sheaths, but also to insert other catheters and introducer sheaths. Thus, cardiac interventions such as percutaneous coronary interventions can also be performed via the 14 French Impella CP introducer sheaths. The single access procedure is already practiced in the U.S., where it was incorporated into Impella CP’s U.S. labeling in January 2020. The confirmation given by MEDCERT GmbH for the single access procedure now gives cardiologists in Europe the option of performing interventional treatments for severe cardiac diseases via just one access site. This method may be beneficial for patients with limited vascular access and may reduce potential complications using only one access site. As a notified body, MEDCERT Zertifizierungs- und Prüfungsgesellschaft für die Medizin GmbH is an organization designated by Germany, as an EU member state, to determine whether medical devices comply with European directives and regulations. MEDCERT GmbH has now confirmed to Abiomed that the single access procedure is possible in Europe as well. More than 170,000 patients worldwide have been treated with Abiomed’s small Impella heart pumps. Impella heart pumps promote heart recovery by taking over partial or full pump function of the heart, depending on the pump type, and relieving the ventricle, thereby supporting blood circulation, stabilizing patients’ hemodynamics and improving blood supply to end organs. In this way, Impella heart pumps can promote the regeneration of the heart muscle, and enable patients to enjoy an improved quality of life. The heart pumps are used in emergency medicine as well as in complex coronary interventions. Impella 2.5®, Impella CP®, Impella CP® with SmartAssist® Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® heart pumps are CE certified and FDA approved for the treatment of heart attack patients with cardiogenic shock. Impella heart pumps assist in restoring cardiac function so the patient can leave the hospital with their own heart. The Impella 2.5 and Impella CP heart pumps are also approved in certain cases to treat patients with advanced heart failure who need to undergo elective percutaneous coronary interventions, e.g. stent implantation or balloon angioplasty, to reopen blocked coronary arteries. The right ventricular heart pump, Impella RP®, is approved for the treatment of certain patients with right heart failure. Source: Company Press Release